ASH Review 2018: Update on Myelodysplastic Syndrome - ppt download
Current concepts in iron deficiency anemia
Barry Skikne, MD | Aplastic Anemia & MDS International Foundation
PDF) Pathogenesis and Management of Iron Deficiency Anemia: Emerging Role of Celiac Disease, Helicobacter pylori, and Autoimmune Gastritis | Barry Skikne - Academia.edu
The Iron Disorders Institute Guide to Anemia: Cumberland House Publishing: 9781581822991: Books - Amazon.ca
Dr. Barry S Skikne M.D., Hematologist (Blood Specialist) | Hematology in Kansas City, KS, 66160 | FindATopDoc.com
Revista de Oncología Clínica
Barry S. Skikne - CMO at TVAX Biomedical | The Org
ESMO 2021 Hematologic Malignancies Panel Discussion | VuMedi
Dr. Barry Skikne, MD, Hematology Specialist - Westwood, KS | Sharecare
BARRY S SKIKNE, MD, Hematology KANSAS CITY, KS - NPI 1902992647
Barry SKIKNE | Celgene, Summit | Hematology | Research profile
Barry SKIKNE | Celgene, Summit | Hematology | Research profile
Laurence Harvey - Wikipedia
a55076c65c36dd96bb36febfb86f970597c39ca27ec6b020e09519b5bbcdc734
Safety and Efficacy of Oral Azacitidine (CC-486) Administered in Extended Treatment Schedules to Patients with Lower-Risk Myelod
Dr. Barry Skikne, MD – Leawood, KS | Hematology
Expert Video - Are clinical trials an option in treatment failure or relapse in AML?
PDF) Improved differential diagnosis of anemia of chronic disease and iron deficiency anemia: A prospective multicenter evaluation of soluble transferrin receptor and the sTfR/log ferritin index | Barry Skikne and Paul Caldron -
Abdulraheem Yacoub on Twitter: "RT @KUcancercenter: Dr. Barry Skikne speaking at #kuASHreview: update on Myelodysplastic Syndrome (#MDS) #KUbloodcancer https://t.co/RWlsBR…" / Twitter
Expert Video - Are clinical trials an option in treatment failure or relapse in AML?
HAEMATOLOGICA：口服阿扎胞苷为缓解期急性髓系白血病患者保持良好的疲劳水平和健康相关的生活质量-MedSci.cn
PDF) Serum form of the erythropoietin receptor identified by a sequence-specific peptide antibody | Barry Skikne - Academia.edu
ASCO 2022 Updates in Leukemia and MDS | VuMedi
Long‐term survival with oral azacitidine for patients with acute myeloid leukemia in first remission after chemotherapy: updated results from the randomized, placebo‐controlled, phase 3 QUAZAR AML‐001 trial - Wei - American Journal
